The Medical Letter on Drugs and Therapeutics
Emtricitabine/Tenofovir Alafenamide (Descovy) for HIV
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Emtricitabine/Tenofovir Alafenamide (Descovy) for HIV
The FDA has approved Descovy (Gilead), a fixed-dose combination of the nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) emtricitabine (FTC) and tenofovir alafenamide (TAF) for use with other antiretroviral agents for treatment of...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Emtricitabine/Tenofovir Alafenamide (Descovy) for HIV
Article code: 1500c
 Electronic, downloadable article - $45

Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.